Coronavirus

From Tenpenny Research Library
Jump to navigation Jump to search

January 26, 2023 - The role of social circle COVID-19 illness and vaccination experiences in COVID-19 vaccination decisions: an online survey of the United States population  "The survey provides useful information about the decision for or against getting vaccinated for COVID-19. The evaluation also showed that those who perceive that loved ones were harmed by the COVID-19 illness were more likely to be vaccinated, but the opposite was true for those who knew someone who had been injured by the COVID-19 vaccine. The large difference in the possible number of fatalities due to COVID-19 vaccination that emerges from this survey and the available governmental data should be further investigated." PDF (775K)

Scientists worry as more Americans say they’ll refuse COVID-19 vaccine  “The vaccine isn’t something we needeven if it is safe,” she says. “People want an easy solution and they think this is it. But it isn’t.” She’s not the only one with misgivings. A Pew Research poll from late September showed that about half of US adults (51 percent) wouldn’t get a COVID-19 vaccine if it was available today — a big drop from the 72 percent who said they’d get one back in May.”

Global Report Novel Coronavirus 2019 n-CoV: “There is no deadly pandemic. The data is clear”

NOTICE OF NO CONSENT” to refuse medical testing and procedures

YOU HAVE MEDICAL RIGHTS
“You are protected by a PATIENT’S BILL OF RIGHTS. You do not have to submit to any medical treatments, including testing or having your temperature taken.”
~ Peggy Hall

https://www.thehealthyamerican.org/s/no-consent-for-medical-testing-thehealthyamerican.pdf

NOTICE AND WARNING
“NO CONSENT FOR MEDICAL TESTING AND TREATMENT”

1. All medical procedures, including testing, must be consensual and performed by a licensed physician in order to be lawful.
2. Non-consensual administration of a medical procedure is felony assault and battery whether or not administered by a licensed physician.
3. You may not conduct any medical procedure or testing on my body (or the bodies of my children) without written consent from me.
4. “Protection” of any “group” such as “the general public” does not suspend my individual rights.
5. Any person administering medicine without the consent of the patient and/or guardian is subject to, and fully liable for major compensation and penalties owed to the victim.
6. Criminal charges may be filed against those who coerce, threaten or perform medical procedures without patient consent.
7. By attempting any non-consensual medical procedure you are agreeing to all terms herein.
8. The United States Constitution prohibits non-consensual medical testing and treatment (4th Amendment.)
9. Additionally, I will invoke any of the numerous state and local laws and codes which call for penalties against the forced application of medicine and/or practicing medicine without a license.
10. I attest and witness that ” I DO NOT CONSENT” to medical testing and treatment.

Written name of individual refusing testing: _ ______________________________________
Signature: ___________________________________________

Date: __________________
Name of Institution requiring testing: _____________________________________________
Written name of person requiring testing:__________________________________________
Signature of person requiring testing: _________________________________ Date: ________

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Moderna, Inc. “We do not expect to recognize significant revenue from sales of potential mRNA medicines unless and until we successfully complete clinical development and obtain regulatory approval for one or more of our investigational medicines. If we seek to obtain regulatory approval for any of our investigational medicines, we expect to incur significant commercialization expenses. Our investigational vaccine against the novel coronavirus (mRNA-1273), which is currently in clinical trials, has been developed rapidly to respond to the global COVID-19 pandemic. We are expending significant efforts to further the rapid development of this potential vaccine and expect to continue to do so over the next 12 months. These efforts have required and will continue to require the expenditure of significant funds and the establishment of significant worldwide infrastructure and partnerships. As a result, we expect we will need substantial additional funding to support our continued operations and pursue our growth strategy. Until we can generate significant revenue from potential mRNA medicines, if ever, we expect to finance our operations through a combination of public or private equity offerings, structured financings and debt financings, government funding arrangements, strategic alliances and marketing, manufacturing, distribution and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our programs.

Texas Supreme Court Reminds Cities There Is No Pandemic Exception to the Constitution “If health regulations “went beyond the necessity of the case and under the guise of exerting a police power …violated rights secured by the Constitution” the court would be bound “to hold such laws invalid.” In other words, even Jacobson does not create the pandemic exception to the Constitution that some seem to believe it does.

Vaccines and Related Biological Products Advisory Committee Meeting February 26, 2021 FDA Briefing Document Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19

June 25, 2021 – Maternal and Child Symptoms Following COVID-19 Vaccination Among Breastfeeding Mothers “Several maternal postvaccination symptoms (allergic reactions, fever, chills, muscle pain, headache, fatigue, and injection site pain) were more common after the second dose.

February 2021 – A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness “A 5-day course of ivermectin resulted in an earlier clearance of the virus compared to placebo (p = 0.005), thus indicating that early intervention with this agent may limit viral replication within the host. In the 5-day ivermectin group, there was a significant drop in CRP and LDH by day 7, which are indicators of disease severity. It is noteworthy that the viral nucleic acid Ct value (indicator of viral load) dropped significantly compared to the placebo group on day 7 and day 14. In the absence of co-morbidity, a 5-day course of ivermectin treatment showed faster SARS-CoV-2 virus clearance compared to the placebo arm (9 vs 13 days; p = 0.02).”

October 21, 2020 – MuLBSTA Score Accurately Predicts Mortality, Outcomes in Hospitalised Patients With COVID-19 “Several clinical characteristics were reviewed, and 6 risk factors were incorporated into the MulBSTA score which included multilobe infiltrate (5 points), absolute lymphocyte count ≤0.8 x 109/L (4 points), bacterial coinfection (4 points), smoking history (previous smoker = 2 points, recent smoker = 3 points), history of hypertension (2 points), and age ≥ 60 years (2 points).

October 20, 2020 – Dr. James Lyons-Weiler at PA Medical Freedom Press Conference 10/20/20 (video)

October 5, 2020 – CDC Flips, Acknowledges Aerosol Spread of COVID-19 “Information Deleted From Website Last Month On September 18, the CDC had added to its existing guidance that the virus is spread “through respiratory droplets or small particles, such as those in aerosols, produced when an infected person coughs, sneezes, sings, talks, or breathes. These particles can be inhaled into the nose, mouth, airways, and lungs and cause infection. The CDC then deleted that guidance on September 21, saying it was a draft update released in error.”

October 4, 2020 – Time to include children in COVID-19 vaccine trials, experts say “In a presentation during the AAP National Conference & Exhibition, Offit, an Infectious Diseases in Children Editorial Board Member and director of the Vaccine Education Center at Children’s Hospital of Philadelphia, noted that the two COVID-19 vaccine trials farthest along in the United States are the trials for Pfizer’s and Moderna’s mRNA vaccines.”

October 1, 2020 – Ensuring Uptake of Vaccines against SARS-CoV-2 “The fact that a vaccine has received Food and Drug Administration (FDA) approval — whether under an Emergency Use Authorization (EUA) or ordinary review processes — is an insufficient basis on which to conclude that it should be required. FDA approval reflects a determination that clinical trial evidence shows that the benefits of a vaccine outweigh its risks. ACIP recommendations reflect broader considerations, including values and preferences of affected groups, implementation issues, and health economic analyses. Overweighting FDA decisions would be particularly problematic for SARS-CoV-2 vaccines because EUAs may be based on very limited evidence and consciously or unconsciously influenced by the intense pressure to speed countermeasures to market.

September 4, 2020 – Why COVID-19 vaccines need to prioritize “superspreaders” “We argue that this pandemic requires a different model for making vaccination choices. After taking care of essential workers, vaccinations should be given to the biggest transmitters of the virus – mostly the young – and only then to the most vulnerable.”

September 2020 – Weekly Updates by Select Demographic and Geographic Characteristics ”

NOTE: Number of deaths reported in this table are the total number of deaths received and coded as of the date of analysis and do not represent all deaths that occurred in that period. Counts of death occurring before or after the reporting period are not included in the table.

*Data during this period are incomplete because of the lag in time between when the death occurred and when the death certificate is completed, submitted to NCHS and processed for reporting purposes. This delay can range from 1 week to 8 weeks or more, depending on the jurisdiction and cause of death.

1Deaths with confirmed or presumed COVID-19, coded to ICD–10 code U07.1.

2Counts of deaths involving pneumonia include pneumonia deaths that also involve COVID-19 and exclude pneumonia deaths involving influenza.

3Counts of deaths involving influenza include deaths with pneumonia or COVID-19 also listed as a cause of death.

4Deaths with confirmed or presumed COVID-19, pneumonia, or influenza, coded to ICD–10 codes U07.1 or J09–18.9.

5Population is based on 2019 postcensal estimates from the U.S. Census Bureau.

August 24, 2020 – Not just antibodies: B cells and T cells mediate immunity to COVID-19 “As there are no licensed CoV vaccines and with the urgency of the ongoing pandemic, controlled human challenge experiments of young healthy volunteers to identify correlates of protection may be necessary to speed up the evaluation of vaccines and to provide definitive data on which immune responses provide durable protection.”

July 21, 2020 – COVID-19 Vaccine Messaging, Part 1 “Official Title: Persuasive Messages for COVID-19 Vaccine Uptake: a Randomized Controlled Trial, Part 1 … This is a scale composed of 4 items measuring the trustworthiness, selfishness, likeableness, and competence of those who choose not to get vaccinated after a vaccine becomes available

June 10, 2020 – Could pressure for COVID-19 drugs lead the FDA to lower its standards? “As a specialist in bioethics and public health, I see troubling signs that suggest the FDA’s new program for expediting reviews of potential therapies for COVID-19 is not working as it should. Instead, its regulatory oversight has been weakened. In its place, I see signs of political interference, inappropriate pressure to authorize products for emergency use, and an overwhelming surge of clinical studies that challenges the FDA’s capacity to carefully scrutinize them before deciding whether they should proceed.”

June 5, 2020 – Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis “Our independent peer reviewers informed us that Surgisphere would not transfer the full dataset, client contracts, and the full ISO audit report to their servers for analysis as such transfer would violate client agreements and confidentiality requirements. As such, our reviewers were not able to conduct an independent and private peer review and therefore notified us of their withdrawal from the peer-review process.”

June 2, 2020 – Covid-19 Treatments and Vaccines Milkin Institute – Airtable.com

April 17, 2020 – Make science evolve into a One Health approach to improve health and security: a white paper “This will revolutionize our ability to understand risk of emerging diseases, predict where and when pathogens could emerge, and design new mitigation strategies, including avoidance behaviors, vaccines and drugs. The background ecological and anthropological data collected by the GVP and other projects will contribute to our knowledge of wildlife biodiversity and distribution, with potential positive conservation benefits.

April 9, 2020 – Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR “The present report describes the establishment of a diagnostic workflow for detection of an emerging virus in the absence of physical sources of viral genomic nucleic acid. Effective assay design was enabled by the willingness of scientists from China to share genome information before formal publication, as well as the availability of broad sequence knowledge from ca 15 years of investigation of SARS-related viruses in animal reservoirs. The relative ease with which assays could be designed for this virus, in contrast to SARS-CoV in 2003, proves the huge collective value of descriptive studies of disease ecology and viral genome diversity.

April 6, 2020 – FDA’s Hahn: No sign China has affected U.S. drug supply during coronavirus pandemic “With pharmaceutical supply chains under immense pressure due to the novel coronavirus, China’s role as a global ingredient producer has come under scrutiny. Despite fears the East Asian nation could shut off the tap for U.S. drugs, the FDA said it hasn’t yet noticed major signs for concern.”

April 4, 2020 – SARS-CoV-2 titers in wastewater are higher than expected from clinically confirmed cases “We then confirmed the identity of the PCR product by direct DNA sequencing. Viral titers observed were significantly higher than expected based on clinically confirmed cases in Massachusetts as of March 25.

April 3, 2020 – The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro “We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARS-CoV-2 able to effect ∼5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.”

April 3, 2020 – Rationale for Vitamin C Treatment of COVID-19 and Other Viruses – Orthomolecular Medicine News Service Editorial Review Board “Supplemental vitamin C, both oral and IV is an excellent and relatively simple and inexpensive treatment for both uninfected individuals at home, and critically-ill individuals in the hospital. It has been proven to be effective in treating many different viral infections, including SARS pneumonia. With early and high dosing at regular intervals, vitamin C can effectively fight against sepsis, hyper-inflammation, and high virus titer to allow ICU patients to recover quickly. Combined with an overall integrative approach to health management, vitamin C, vitamin D, zinc, and other essential vitamins and minerals can effectively prevent and treat COVID-19. However, the mechanisms and relative benefits of different doses, both oral/liposomal and IV need further study.

April 2020 – Guidance for Certifying Deaths Due to Coronavirus Disease 2019 (COVID–19) (pdf)

March 31, 2020 – Patients with COVID-19 GI symptoms experience delayed diagnosis, viral clearance “Clinicians should recognize that new-onset, acute digestive symptoms in a patient with a possible COVID-19 contact should at least prompt consideration of the illness, particularly during times of high COVID-19 incidence and prevalence,” Hou and colleagues wrote. “Failure to recognize these patients early and often may lead to unwitting spread of the disease among outpatients with mild illness who remain undiagnosed and unaware of their potential to infect others.”

March 28, 2020 – National Coronavirus Response A Road Map To Reopening (pdf) “Trigger to Begin Manufacturing Scale-Up and Vaccine or Therapeutic Prioritization Planning. As soon as a vaccine or therapeutic looks promising in pivotal clinical trials (i.e., it has been shown to be safe and looks like it will also be effective), the US government should work with industry to begin planning for mass manufacturing, distribution, and administration. New provisions enacted under the recently passed Coronavirus Aid, Relief, and Economic Security Act allow for large-scale manufacturing of promising therapies, in advance of approval, to help make sure there will be adequate supply available for mass distribution, should a product demonstrate that it is safe and effective and win regulatory approval.”

March 27, 2020. – Relationship between the ABO Blood Group and the COVID-19 Susceptibility “The results showed that blood group A was associated with a higher risk for acquiring COVID-19 compared with non-A blood groups, whereas blood group O was associated with a lower risk for the infection compared with non-O blood groups.” whereas blood group O was associated with a lower risk for the infection compared with non-O blood groups.”

March 26, 2020 – Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn “The infant’s repeatedly negative RT-PCR test results on nasopharyngeal swabs are difficult to explain, although these tests are not always positive with infection. IgG antibodies can be transmitted to the fetus through the placenta and appear later than IgM. Therefore, the elevated IgG level may reflect maternal or infant infection.”

March 26, 2020 – Covid-19 — Navigating the Uncharted “The median age of the patients was 59 years, with higher morbidity and mortality among the elderly and among those with coexisting conditions (similar to the situation with influenza); 56% of the patients were male. Of note, there were no cases in children younger than 15 years of age. Either children are less likely to become infected, which would have important epidemiologic implications, or their symptoms were so mild that their infection escaped detection, which has implications for the size of the denominator of total community infections.

March 26, 2020 – Covid-19 — Navigating the Uncharted “Achieving a better understanding of the pathogenesis of this disease will be invaluable in navigating our responses in this uncharted arena. Furthermore, genomic studies could delineate host factors that predispose persons to acquisition of infection and disease progression.”

March 23, 2020 – New Guidelines on CPR When COVID-19 Is Known or Suspected – Avoiding infection during aerosol-generating procedures – Special precautions should be taken when resuscitating people in cardiac arrest with known or suspected COVID-19 coronavirus, according to guidance from the American Heart Association (AHA).

March 20, 2020 – Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial full text) “Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported of untreated patients in the literature. Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination.”

March 20, 2020 – How doctors can use technology to cut COVID-19 infection risks “The COVID-19 pandemic paved the way this week for the expansion of telehealth. You might be thinking, that’s great, but now isn’t the best time to be implementing a new IT solution. Offering telehealth services doesn’t have to be complicated and it could prevent you and your patients from catching the virus. And under newly announced HIPAA “enforcement discretion,” you don’t have to worry about running afoul of HIPAA law.

March 18, 2020 – Catching Up to Coronavirus: Top 60 Treatments in Development “According to the Chinese registry, numerous Chinese authorities, hospitals, and companies continue to study treatments outside the auspices of their original developers, or any developers. One most recent example of that is the First Affiliated Hospital of Wenzhou Medical University, whose researchers have launched a pair of clinical trials in China assessing thalidomide—one as an adjuvant treatment for prevention or treatment of lung injury caused by COVID-19 (NCT04273529); the other a study assessing thalidomide plus low-dose hormone adjuvant therapy for patients with severe COVID-19 (NCT04273581)—after the drug achieved positive results in the treatment of patients with severe H1N1.

February 28, 2020 – Responding to Covid-19 — A Once-in-a-Century Pandemic? “The long-term challenge — improving our ability to respond to outbreaks — isn’t new. Global health experts have been saying for years that another pandemic whose speed and severity rivaled those of the 1918 influenza epidemic was a matter not of if but of when. The Bill and Melinda Gates Foundation has committed substantial resources in recent years to helping the world prepare for such a scenario.

February 25, 2020 – Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies “Much remains to be learnt about the virus, its biological properties, epidemiology, etc. At this early stage, there is also a lack of information about specific immune responses against SARS-CoV-2, which presents a challenge for vaccine development. This study has sought to assist with the initial phase of vaccine development by providing recommendations of epitopes that may potentially be considered for incorporation in vaccine designs. Despite having limited understanding of how the human immune system responds naturally to SARS-CoV-2, these epitopes are motivated by responses they have recorded in SARS-CoV (or, for the case of T cell epitopes, to at least confer MHC binding), and the fact that they map identically to SARS-CoV-2, based on the available sequence data (as of 21 February 2020).”

February 25, 2020 – Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection (COVID-19) “This is a phase I, open-label, dose ranging clinical trial in males and non-pregnant females, 18 to 55 years of age, inclusive, who are in good health and meet all eligibility criteria. This clinical trial is designed to assess the safety, reactogenicity and immunogenicity of mRNA-1273 manufactured by ModernaTX, Inc. mRNA-1273 is a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized spike (S) protein of SARS-CoV-2.”

January 23, 2020 – Coronavirus Infections—More Than Just the Common Cold “Vaccines, which have adapted approaches used for SARS-CoV or MERS-CoV, are also being pursued. For example, scientists at the National Institute of Allergy and Infectious Diseases Vaccine Research Center have used nucleic acid vaccine platform approaches.6 During SARS, researchers moved from obtaining the genomic sequence of SARS-CoV to a phase 1 clinical trial of a DNA vaccine in 20 months and have since compressed that timeline to 3.25 months for other viral diseases. For 2019-nCoV, they hope to move even faster, using messenger RNA (mRNA) vaccine technology. Other researchers are similarly poised to construct viral vectors and subunit vaccines.” “Comment: Anthony S. Fauci, MD is one of the authors of this article.

January 10, 2020 – Influenza vaccination and respiratory virus interference among Department of Defense personnel during the 2017–2018 influenza season “The virus interference phenomenon goes against the basic assumption of the test-negative vaccine effectiveness study that vaccination does not change the risk of infection with other respiratory illness, thus potentially biasing vaccine effectiveness results in the positive direction. This study aimed to investigate virus interference by comparing respiratory virus status among Department of Defense personnel based on their influenza vaccination status. Furthermore, individual respiratory viruses and their association with influenza vaccination were examined.”

2020 – Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases “The patent analysis of coronavirus related biologics includes therapeutic antibodies, cytokines, and nucleic acid-based therapies targeting virus gene expression as well as various types of vaccines. More than 500 patents disclose methodologies of these four biologics with the potential for treating and preventing coronavirus infections, which may be applicable to COVID-19. The information included in this report provides a strong intellectual groundwork for the ongoing development of therapeutic agents and vaccines.”

SARS CoV-1

November 21, 2017 – Immune responses in influenza A virus and human coronavirus infections: an ongoing battle between the virus and host “This brief review outlines how the host immune response plays both protective and pathogenic roles in respiratory virus infections. To decrease the burden that respiratory viruses place on society, increased understanding of all aspects of the host immune response remains a critical research goal.” … “A major goal of IAV and CoV vaccine development is to develop vaccines able to induce broadly acting antibodies; these efforts require more precise definition of useful conserved protective antibody epitopes.”

April 20, 2012 – Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. (full text) “Mean lung lesion scores two days after challenge were similar for all groups and indicated a moderate to severe degree of cellular infiltration (p>0.05 for each, Anova) (figure 8A). However, eosinophil scores were significantly different between groups (p<0.001, Anova) with significantly lower scores for nonvaccine groups than for vaccine groups of both mouse strains (p<0.001 for all comparable group comparisons, Tukey’s HSD). Eosinophil scores for the vaccine groups were not different between the two mouse strains (p>0.05, t test) (figure 8B). Photomicrographs of the different vaccine and mouse strain groups are shown in figure 9. Both vaccines in both mouse strains exhibited significant cellular infiltrations that included numerous eosinophils as shown in the MBP stained sections, a finding consistent with a hypersensitivity component of the pathology. Prior influenza vaccine did not lead to an eosinophil infiltration in the lung lesions after challenge.”

August 22, 2005 – Chloroquine is a potent inhibitor of SARS coronavirus infection and spread (full text) “We report, however, that chloroquine has strong antiviral effects on SARS-CoV infection of primate cells. These inhibitory effects are observed when the cells are treated with the drug either before or after exposure to the virus, suggesting both prophylactic and therapeutic advantage.

November 2004 – The SARS Epidemic And Its Aftermath in China: A Political Perspective “I still say China sent hundreds if not thousands, and most directed to NYC. to seed the population. Maybe that is why Nancy Pelosi was telling people to go to China town. “The government’s heavy reliance on quarantine during the epidemic also raises a question about the impact of future disease control measures and the worsening of the human rights situation in China. This question, of course, is not unique to China—even countries like the United States are debating whether it is necessary to apply mandatory approaches to confront health risks more effectively. The Model Emergency Health Powers pushed by the Bush administration would permit state governors in a health crisis to impose quarantines, limit people’s movements.